Gates Foundation-backed fund invests in rapid diagnostics maker Atomo

Sydney-based Atomo Diagnostics picked up AU$4.5 million ($3.5 million) in equity from a number of investors, including the Gates Foundation-backed Global Health Investment Fund. Atomo makes rapid diagnostic tests for HIV and malaria that require just a drop of blood.

The company’s AtomoRapid HIV tool integrates lancing, blood collection and delivery components into one device. After pricking the skin, the lancet is locked out of the way and a capillary tube automatically collects the 10 microliters of blood required for the AtomoRapid HIV test. The blood is then automatically delivered to the HIV test strip, which provides results within 15 minutes.

Combining these different components into one device reduces opportunities for error, cutting down on false negatives while increasing the speed of diagnosis. Current HIV test kits use multiple devices and require the manual collection and delivery of the blood sample to the test itself, the company said.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

The company hopes to replace these tests with AtomoRapid platform. In addition to diagnosing HIV, Atomo also markets AtomoRapid Malaria, which tests for the mosquito-borne disease and distinguishes between malaria strains. And a hepatitis C test, as well as a multitest platform, are in the works.

The investment also sees Dr. Curt LaBelle, a managing partner at the Global Health Investment Fund, join Atomo’s board of directors. Atomo received a AU$7.8 million ($6 million) loan from the GHIF earlier this year, and in 2015, won a AU$1.8 million ($$1.3 million) grant from the New South Wales Medical Device Fund to develop a version of its HIV test with a built-in digital reader.

“Our fund is pleased to provide additional support to Atomo Diagnostics through this equity investment. Atomo has developed a unique platform enabling quick, accurate and affordable point-of-care and consumer diagnostics,” LaBelle said in a statement.

- here's the statement

Related Articles:
Australia's Atomo secures $6M to deploy its rapid HIV self-diagnostic in emerging markets
Roche launches rapid HIV, hep C tests in Europe
Scientists unveil rapid diagnostic for urinary tract infections
Diagnostics companies jump into rapidly growing market for point-of-care superbug tests

Suggested Articles

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.